MDM2 and cancer: Many inhibitors of RING finger E3 ligases have demonstrated considerable therapeutic potential in preclinical models and clinical trials of cancer immunotherapy or combination therapy, among which the most studied inhibitors include the IAP family, MDM2, pVHL, Skp2, and β-TrCP [159,164,182,183,204].